Pharmafile Logo
Pharmafocus logo
Advanced Search

US

Showing 15 posts of 327 posts found.

US health industry outlines cost saving plans

June 3, 2009
Sales and Marketing US, US healthcare, healthcare, industry

The US healthcare industry has said how it contribute to President Obama’s drive to cut healthcare costs, and help save …

News

Companies poised for swine flu vaccine drive

May 29, 2009
Research and Development, Sales and Marketing US, h1n1, vaccines

Pharmaceutical manufacturers now have access to the swine flu seed virus that can be used to start full-blown production of …

News

Ranbaxy woes continue with antibiotic recall

May 6, 2009
Sales and Marketing Ranbaxy, US

Indian drugmaker Ranbaxy Laboratories has recalled an antibiotic on sale in the US, suggesting that it still has some way …

News

Coast first casualty in US overhaul of IRB system

May 5, 2009
Research and Development FDA, US

A US company offering institutional review board services to sponsors of clinical trials has been forced to close its doors …

News

Pfizer opens $200m R&D site in St Louis

April 21, 2009
Research and Development Pfizer, US

News

Committee approves limited use of Seroquel in depression

April 9, 2009
Research and Development, Sales and Marketing AZ, Seroquel, US

An FDA advisory committee has concluded that safety concerns mean that Seroquel XR should not be used to treat anxiety, …

News

US prescription growth stalls in 2008

April 3, 2009
Sales and Marketing US

US prescription sales growth was just 1.3% in 2008, well down on the typical 5%-plus in recent years, according to …

News

Biosimilars: time for an approval pathway in the US

March 23, 2009
Research and Development, Sales and Marketing US, generics

Congress has received another bill seeking to establish a biosimilars approval pathway in the US. HR 1427 represents the latest …

News

Sanofi boosted by Multaq vote of approval

March 19, 2009
Research and Development, Sales and Marketing FDA, Multaq, Sanofi, US

An FDA committee has recommended Sanofi-Aventis' new atrial fibrillation treatment Multaq, the company's most important late-stage drug. The FDA cardiovascular …

News

Biosimilars bill offers 12 years’ marketing exclusivity

March 19, 2009
Research and Development US, generics

The US moved one step closer to creating a market for biosimilars – substitutable versions of branded biologic drugs – …

News

Obama ends stem cell funding ban

March 10, 2009
Research and Development US, stem cell

President Obama has lifted the US ban on federal funding for new stem cell research, signalling another marked departure in …

News

Obama makes ‘downpayment’ on US healthcare reform

March 5, 2009
Research and Development US, healthcare

President Barack Obama has reiterated his aim of bringing universal healthcare to the US and has put a $76.8 billion …

News

R&D tax credits among anticipated changes for US healthcare

February 24, 2009
Research and Development US, healthcare

With the election of Barack Obama, widespread changes are anticipated for US healthcare and ultimately for the pharmaceutical industry. Although …

News

FDA finalises transgenic animals guide

January 23, 2009
Research and Development, Sales and Marketing FDA, US, reg

The route map for companies wishing to sell medicines made in genetically-engineered animals has been drawn up by the FDA. …

News

Declaring doctor payments

December 16, 2008
Research and Development, Sales and Marketing ABPI, EFPIA, Europe, UK, US, ethics, industry relations, payments

A number of pharmaceutical companies in the US have recently announced they will declare all the payments to healthcare professionals. …

Feature
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026